|
Re: The dangers of plasma torches
|
|
PyroGenesis Canada Inc
|
Jan 25, 2021 09:44PM
|
|
Re: Now published: Rationale, design, and baseline characteristics of the BETonMACE trial
|
1
|
Resverlogix Corp.
|
Sep 16, 2019 02:38PM
|
|
Re: Now published: Rationale, design, and baseline characteristics of the BETonMACE trial
|
1
|
Resverlogix Corp.
|
Sep 16, 2019 03:37PM
|
|
Re: Sanofi Resverlogix connection?
|
1
|
Resverlogix Corp.
|
Jan 13, 2019 10:54PM
|
|
The dangers of plasma torches
|
1
|
PyroGenesis Canada Inc
|
Jan 25, 2021 09:35PM
|
|
Re: The dangers of plasma torches
|
1
|
PyroGenesis Canada Inc
|
Jan 25, 2021 10:59PM
|
|
Re: I have a growing concern....
|
1
|
Resverlogix Corp.
|
Feb 28, 2020 01:44PM
|
|
Re: RVX buyout projection at $30 US minimum
|
1
|
Resverlogix Corp.
|
Nov 01, 2018 09:54PM
|
|
third eye loan
|
1
|
Resverlogix Corp.
|
Mar 06, 2019 11:09PM
|
|
shareholder participation in share issuance
|
1
|
PyroGenesis Canada Inc
|
Oct 15, 2020 11:18PM
|
|
Re: RVX-297 vs RVX-208 for autoimmune indications
|
2
|
Resverlogix Corp.
|
Jan 09, 2019 04:16PM
|
|
Re: Contest
|
2
|
Resverlogix Corp.
|
Sep 16, 2019 01:32PM
|
|
Re: RESVERLOGIX ANNOUNCES WARRANT EXERCISE INCENTIVE PROGRAM
|
2
|
Resverlogix Corp.
|
Nov 25, 2019 06:50PM
|
|
Re: RESVERLOGIX ANNOUNCES WARRANT EXERCISE INCENTIVE PROGRAM
|
2
|
Resverlogix Corp.
|
Nov 25, 2019 07:01PM
|
|
Re: Congestive heart failure
|
2
|
Resverlogix Corp.
|
Nov 25, 2019 07:06PM
|
|
Re: Top Line Mid Year
|
2
|
Resverlogix Corp.
|
Mar 11, 2019 03:38PM
|
|
Re: BIO CEO Slides Up
|
2
|
Resverlogix Corp.
|
Sep 18, 2019 07:00PM
|
|
Re: MACE Event rate,....
|
2
|
Resverlogix Corp.
|
Feb 28, 2019 04:49PM
|
|
Re: We're back on the buy-in list for Jul 05 2018
|
2
|
Resverlogix Corp.
|
Jul 05, 2018 11:11PM
|
|
Re: ACE2 and Covid
|
2
|
Resverlogix Corp.
|
Sep 25, 2020 06:29PM
|
